Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Santhera Sets Out Launch Strategy For CHMP-Backed Duchenne Drug

Oct 13 2023

• By Kevin Grogan

Eklund_Dario_1200 — CEO Dario Eklund • Source: Santhera

Related Content

Santhera’s Vamorolone For DMD Among Orphan Drugs Up For EU Marketing Decision

Oct 11 2023

Santhera Pulls EU Filing For Failed DMD Candidate

Nov 11 2020

Santhera Finalizes Vamorolone Filings And Now Seeks Funds

Oct 31 2022

With Duchenne Filing Due, Santhera Moves Vamorolone Into Becker Muscular Dystrophy

Aug 22 2022

Santhera Finds ‘Elegant Solution’ For Its Finances With Catalyst DMD Drug Deal

Jun 21 2023

Related Companies

Santhera Pharmaceuticals

Chiesi Farmaceutici S.p.A.

Reveragen BioPharma, Inc.

PTC Therapeutics, Inc.

Catalyst Pharmaceuticals, Inc.

Additional Topics

Launches Rare Diseases Business Strategies Approvals Regulation Reimbursement BioPharmaceutical

More from New Products

More from Scrip

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window